Home > News > Lixisenatide—Once-daily Glucagon-like Peptide-1 Receptor Agonist in the Management of Type 2 Diabetes
Diabetes
Read Time: 4 mins

Lixisenatide—Once-daily Glucagon-like Peptide-1 Receptor Agonist in the Management of Type 2 Diabetes

Published Online: March 20th 2012 US Endocrinology, 2011;7(2):104-9 DOI: http://doi.org/10.17925/USE.2011.07.02.104
Authors: Celeste C L Quianzon, Mansur E Shomali
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

The glucagon-like peptide-1 receptor agonist diabetes medications have become important due to their unique features, such as their potency of glycosylated hemoglobin (HbA1C) lowering, durability of effect, glucose-depending insulin secretion resulting in a low risk of hypoglycemia, glucagon suppression, and weight loss. Lixisenatide is an investigational compound in this class, exhibits all of these features, and has some unique properties, which are highlighted in this review. The pharmacology of lixisenatide, the results of recent clinical trials investigating this agent, and its potential role in the management of type 2 diabetes will be discussed.

Keywords

Lixisenatide, glucagon-like peptide-1 receptor agonist, type 2 diabetes

Article:

Type 2 diabetes is a progressive disease of the beta cells characterized by declining insulin secretion and varying degrees of insulin resistance resulting in hyperglycemia. It is a chronic progressive disease of increasing incidence. In the USA, 25.6 million people aged over 20 years have type 2 diabetes1 and the prevalence is projected to increase to 36 million people in the next 20 years.2 This trend follows that of the obesity epidemic.

Type 2 diabetes is a progressive disease of the beta cells characterized by declining insulin secretion and varying degrees of insulin resistance resulting in hyperglycemia. It is a chronic progressive disease of increasing incidence. In the USA, 25.6 million people aged over 20 years have type 2 diabetes1 and the prevalence is projected to increase to 36 million people in the next 20 years.2 This trend follows that of the obesity epidemic. Patients with type 2 diabetes are at increased risk of microvascular and macrovascular complications (neuropathy, renal disease, retinopathy, myocardial infarction, cerebrovascular accident, peripheral vascular disease). Most patients need lifestyle changes and polypharmacy to control hyperglycemia.

The American Association of Clinical Endocrinologists and American Diabetes Association guidelines recommend lifestyle changes and metformin as first-line therapy.3,4 The glucagon-like peptide-1 (GLP-1) receptor agonist class of medications may be used, typically as part of combination therapy, and may have certain advantages over older medications. GLP-1 receptor agonists stimulate insulin secretion in a glucose-dependent manner (thus having a low risk of hypoglycemia), suppress glucagon secretion, improve beta cell function, slow down gastric emptying, and promote early satiety and consequent weight loss.5,6 In addition, GLP-1 agonists have potential cardiovascular benefits with weight reduction, improvements in lipid profile and blood pressure, and decreased markers for cardiovascular risk and inflammation (including C-reactive protein).7 GLP-1 receptor agonists approved by the US Food and Drug Administration are twice-daily exenatide (Byetta®; Amylin Pharmaceuticals, Inc. and Lilly USA, LLC) and once-daily liraglutide (Victoza®; Novo Nordisk). This article reviews lixisenatide (Lyxumia®, AVE0010, ZP10), an investigational once-daily GLP-1 receptor agonist in phase III development for the treatment of type 2 diabetes, which is being developed by Sanofi-aventis under license from Zealand Pharma A/S.8

Pharmacology
Lixisenatide is a 44-amino-acid peptide based on exendin-49 and modified to avoid rapid degradation by dipeptidyl peptidase-IV.10 The modification consists of the deletion of one proline residue and addition of six lysine residues at the C-terminal.11 While the affinity of exendin-4 for the GLP-1 receptor is similar to that of human GLP-1,9 the affinity of lixisenatide for the GLP-1 receptor is four times greater than that of human GLP-19,12 (see Figure 1 and Table 1). Lixisenatide is also highly selective for the GLP-1 receptor.13 Pharmacokinetics studies show that maximum lixisenatide plasma concentration (Cmax) of 84 pg/ml is seen two hours (tmax) after the subcutaneous injection of lixisenatide 20 μg.14 The half-life (t½) is 2.6 ± 1 hours.15 Lixisenatide is filtered in the glomerulus and degraded in the renal tubules.15 Pharmacokinetic parameters for lixisenatide and the other GLP-1 receptor agonists are shown in Table 1.

Preclinical Studies
In a study using rat insulinoma cell line INS-1, lixisenatide protected B-cells against fatty acid and cytokine-induced apoptosis9,16 and inhibition of cytokine-induced apoptosis was significantly greater with lixisenatide and exendin-4 than with human GLP-1. Moreover, the combination of insulin glargine with lixisenatide or exendin-4 significantly reduced apoptosis compared with each agent alone.16

The insulin secretion pattern was studied in isolated pancreas from male Zucker diabetic fatty (ZDF) rats treated with lixisenatide and compared with isolated pancreas from lean and obese ZDF rats not treated with lixisenatide.17 Biphasic insulin secretion was preserved in the lixisenatide-treated obese ZDF rats, similar to what happened in lean controls, but was absent in older obese ZDF rats.17 In a study using human islet cells, lixisenatide showed dose-dependent improvement of glucose-stimulated insulin secretion.18

Improvement of oral glucose tolerance with lixisenatide was shown in animal studies (obese ZDF rats, db/db mice, and dogs).12,19,20 Decreased post-prandial glucose excursion following a mixed meal was seen in mongrel dogs.21 Marked reductions in glucose levels12,19,20 and glycosylated hemoglobin (HbA1C)19 were shown in lixisenatide-treated animals compared with saline-treated animals.

In a comparison study of dogs treated with lixisenatide or liraglutide, blood glucose excursion following glucose challenge in oral glucose tolerance tests was significantly lower in dogs treated with lixisenatide. A similar effect was seen in C57BL/6J mice following a liquid meal.22 Starting at different doses, both lixisenatide (1 μg/kg) and liraglutide (≥500 μg/kg) inhibited gastric emptying in Wistar rats.22 Lixisenatide was shown to be cardioprotective in a study on isolated Langendorff-perfused rat hearts in which the left anterior descending coronary artery was transiently occluded for 45 minutes and then reperfused for 120 minutes. There was significant reduction in the infarct size with lixisenatide compared with vehicle control.23

Phase II Studies
A dose-finding study was undertaken in patients with type 2 diabetes not controlled by metformin. This was a multinational, 13-week, randomized, double-blind, parallel-group, placebo-controlled study that enrolled 542 patients inadequately controlled after at least three months of metformin therapy.24 Participants had a mean age of 56 ± 9 years with mean disease duration of 6.6 ± 5 years, mean body mass index (BMI) of 31.9 ± 4 kg/m2, and mean baseline HbA1C of 7.5 ± 0.6 %. Participants were randomized to one of 12 groups: lixisenatide (5, 10, 20 or 30 μg) administered once or twice daily or four volume-matched placebo treatments administered twice daily. All lixisenatide groups experienced dose-dependent reductions in HbA1C ranging from 0.47 % to 0.76 % in the once-daily regimen and from 0.65 % to 0.87 % in the twice-daily regimen compared with placebo (see Figure 2).24

Secondary efficacy endpoints were the percentage of patients achieving HbA1C of <7 % and <6.5 %, changes in body weight, fasting plasma glucose, and two-hour post-prandial plasma glucose following a standardized breakfast. By the end of the study (week 13), significantly higher proportions of patients achieved HbA1C <7 % in lixisenatide-treated groups (47–69 % in once-daily and 51–77 % in twice-daily groups) compared with the placebo group (32 %). A dose-dependent reduction in body weight was seen in lixisenatide-treated patients, which was significant in the 20 μg once-daily (-3.01 ± 0.41 kg), 30 μg once-daily (-3.47 ± 0.41 kg), and 30 μg twice-daily (-3.89 ± 0.41 kg) groups compared with placebo (-1.94 ± 0.32 kg).24 Significant reductions in fasting plasma glucose were observed in the 30 μg once-daily (-23.76 ± 4.50 mg/dl), 10 μg twice daily (-17.64 ± 4.32 mg/dl), 20 μg twice-daily (-20.34 ± 4.50 mg/dl), and 30 μg twice-daily (-25.56 ± 4.50 mg/dl) groups compared with placebo (-3.78 ± 3.42 mg/dl).24 Mean two-hour post-prandial glucose concentrations in all lixisenatide groups showed a significant reduction by comparison with placebo.24

The study indicated that efficacy was similar between the once- and twice-daily regimens and that there was a dose–response relationship. A dose of 20 μg lixisenatide once daily demonstrated the best efficacy:tolerability ratio. The data suggest further increases in the dose may not provide added benefit.

In a phase II randomized, double-blind, placebo-controlled study involving 64 patients, lixisenatide once or twice daily was added to metformin and/or a sulfonylurea for 28 days. The study measured the effects of lixisenatide on post-prandial change in blood glucose following a standardized breakfast and on levels of fasting and mean plasma glucose and HbA1C. It also evaluated the safety and tolerability of the drug.25 The lixisenatide dose started at 5 μg subcutaneous once daily or twice daily and was increased by 2.5 μg every five days to a maximum dose of 20 μg. On day 28, post-prandial blood glucose levels following a standardized breakfast, as well as mean plasma glucose and HbA1C levels, were significantly reduced in both the once-daily and twice-daily lixisenatide 20 μg groups compared with placebo.25

Phase III Clinical Trial Program
The GetGoal clinical trial program initially consisted of nine phase III trials evaluating the efficacy and safety of lixisenatide in the treatment of patients with type 2 diabetes as monotherapy or in combination with different oral antidiabetes agents and/or insulin. Additional studies have been added to the GetGoal clinical program, including randomized studies comparing lixisenatide to sitagliptin and a large clinical trial evaluating cardiovascular outcomes with lixisenatide in a type 2 diabetes patient who had had a recent acute coronary syndrome. The trials began in May 2008 and 4,300 patients have been enrolled in total.26 At the time of writing, the results of some of these trials have been made available as press releases, or have been presented at scientific meetings and published in abstract form. Table 2 shows a summary of the clinical trial program.

GetGoal-Mono
GetGoal-Mono was a 12-week, double-blind, randomized controlled trial that assessed the efficacy and safety of lixisenatide as monotherapy for type 2 diabetes.27 A total of 361 type 2 diabetes patients not on any diabetes medication were randomized to one of four groups: lixisenatide two-step titration (10 μg once daily for one week, followed by 15 μg once daily for one week, and 20 μg once daily thereafter; n=120), lixisenatide one-step titration (10 μg once daily for two weeks, and 20 μg once daily thereafter; n=119), placebo two-step titration (n=61), or placebo one-step titration (n=61). Patients had a mean age of 54 years, mean disease duration of 2.5 years, and HbA1C in the range 7–10 %.

In the lixisenatide groups, HbA1C decreased significantly (p<0.0001) by comparison with placebo (lixisenatide two-step group -0.73 ± 0.12 %; lixisenatide one-step group -0.85 ± 0.12 %; placebo -0.19 ± 0.12 %). At the end of the study, the lixisenatide groups included significantly more patients with HbA1C ≤6.5% (lixisenatide two-step group 31.9 %; lixisenatide one-step group 25.4 %; placebo 12.5 %) and HbA1C <7.0 % (lixisenatide two-step group 52.2 %; lixisenatide one-step group 46.5108 %; placebo 26.8108 %). They also had significantly higher reductions in two-hour post-prandial glucose levels (lixisenatide twostep group -81.18 ± 4.56 mg/dl; lixisenatide one-step group -98.46 ± 9.9 mg/dl; placebo -11.7 ± 10.08 mg/dl) and fasting plasma glucose levels (lixisenatide two-step group -12.24 ± 4.5 mg/dl; lixisenatide onestep group -16.02 ± 4.5 mg/dl; placebo 3.42 ± 4.68 mg/dl).27

GetGoal-L-Asia
GetGoal-L-Asia was a 24-week multicenter, randomized, double-blind, placebo-controlled clinical trial that evaluated the efficacy and safety of lixisenatide 20 μg once daily in 311 patients with type 2 diabetes (mean age 58 years, disease duration 14 years, and BMI 25 kg/m2) from Japan, South Korea, Taiwan, and the Philippines who were inadequately controlled with basal insulin and/or a sulfonylurea.28

At week 24, lixisenatide had significantly reduced mean HbA1C levels from baseline (-0.77 ± 0.137 %) compared with placebo (0.11 ± 0.131 %; least squares [LS] mean difference -0.88 [95 % CI -1.116 to 0.650]). The percentages of patients on lixisenatide who achieved HbA1C <6.5 % and <7 % were 17.8 % and 35.6 %, respectively, compared with 1.3 % and 5.2 %, respectively, in the placebo group (p<0.0001).28 Other measures of efficacy also were significantly improved (see Table 3).28

GetGoal-X
GetGoal-X compared lixisenatide to exenatide in a 24-week multicenter, randomized, open-label, parallel-group study of 634 type 2 diabetes patients insufficiently controlled on metformin.29 The patients had a mean age of 57.4 years, a disease duration of 6.8 years, a BMI of 33.6 kg/m2, and HbA1C levels of 8 %. The decrease in HbA1C with lixisenatide (-0.79 ± 0.05 %) was comparable with that seen with exenatide (-0.96 ± 0.05 %; LS mean difference 0.17 [95 % CI 0.03–0.30]; p=0.17). Similar percentages of patients achieved HbA1C <7 % with lixisenatide (48.5 %) and with exenatide (49.8 %). The mean decrease in body weight was comparable between the lixisenatide and exenatide groups.29

GetGoal-S
GetGoal-S, a 24-week randomized, double-blind, placebo-controlled clinical study, evaluated the efficacy and safety of lixisenatide in type 2 diabetes patients insufficiently controlled on sulfonylurea and/or metformin. In the study, 859 patients were randomized to either lixisenatide or placebo.30 Doses were increased in a step-wise manner to 20 μg once daily in both groups.

As an add-on therapy to sulfonylurea with or without metformin, lixisenatide significantly reduced HbA1C levels and improved two-hour post-prandial glucose and fasting plasma glucose levels compared with placebo.30 Moreover, patients on lixisenatide experienced a significant decrease in body weight compared with those on placebo.30 At 24 weeks, lixisenatide significantly reduced HbA1C compared with placebo (-0.85 versus -0.10%; p<0.0001). Lixisenatide also significantly improved two-hour PPG (after a standardized meal test) (-6.19 versus -0.21 mmol/l), FPG (-0.99 versus -0.36 mmol/l), and body weight (-1.76 versus -0.93 kg) and increased the proportion of patients achieving HbA1C <7.0 % (36.4 versus 13.5 %) (p<0.0001). GetGoal-L
GetGoal-L is another 24-week clinical study in which 495 patients were randomized either to lixisenatide or placebo in addition to basal insulin with or without metformin. Compared with placebo, lixisenatide significantly decreased mean HbA1C (p=0.0002), improved post-prandial glucose following a standardized meal (p<0.0001), and reduced mean body weight (p<0.0001). Adverse Effects
Gastrointestinal Adverse Reactions
Gastrointestinal adverse reactions to lixisenatide were frequently observed in clinical trials. Nausea was the most frequent event—the incidence ranged from 20 % to 40 % in the lixisenatide arm compared with 4–5 % in the placebo arm24, 26–29—but it was transient and dose-dependent.

Other reported gastrointestinal reactions included vomiting, diarrhea, constipation, dyspepsia, abdominal distension, and abdominal pain.11 In the GetGoal-X study, nausea was experienced less frequently with lixisenatide 20 μg once daily (24.5%) than with exenatide 10 μg twice daily (35.1 %) [p<0.05].29 Incidences of diarrhea (10.4% and 13.3 %) and vomiting (10.1 % and 13.3 %) in the lixisenatide and exenatide groups, respectively, were also similar.29

Hypoglycemia
Symptomatic hypoglycemia has been reported with lixisenatide as monotherapy27 and in combination with other diabetes agents24 and/or insulin.28 No case of severe hypoglycemia has been reported.24,28,29 Symptomatic hypoglycemia was reported in more patients on lixisenatide 20 μg once daily added to basal insulin and/or sulfonylurea (42.9 %) than in patients on placebo (23.6 %).28

The rate of symptomatic hypoglycemia in the lixisenatide group was reduced if patients taking a sulfonylurea were excluded (lixisenatide 31.8 %; placebo 28.3 %).28 The risk of symptomatic hypoglycemia was not significantly increased with lixisenatide 20 μg once daily as an add-on to sulfonylurea with or without metformin compared to placebo at week 24.30 In the GetGoal-X study, patients taking lixisenatide had six-fold fewer hypoglycemic events and three-fold fewer instances of symptomatic hypoglycemia (2.5 %) than patients taking exenatide (7.9 %) [p<0.05].29

Antibodies to Lixisenatide
It is postulated that antibody formation may decrease the effect of GLP-1 agonists on glucose control.11 The rate of antibody formation in patients treated with lixisenatide ranged from 43.1 % with lixisenatide 10 μg once daily to 71.2 % with lixisenatide 20 μg twice daily;24 however, no differences were observed in the efficacy and safety profile of lixisenatide when given to patients with or without antibodies.24

Other Reported Adverse Effects
Reported rates of dizziness and headache with lixisenatide are similar to those reported in placebo groups.24 One patient taking lixisenatide 30 μg once daily experienced loss of consciousness of a few seconds’ duration, which led to withdrawal from the study.24 One patient taking lixisenatide 10 μg once daily discontinued the medication three weeks into the study following two separate allergic reactions 10 minutes after receiving the drug; on the first occasion, the patient developed pruritus, and three days later the patient had swollen lips and tongue and difficulty breathing. The events were resolved with an oral antihistamine.24 Two cases of urticaria occurred with lixisenatide (compared to three with placebo).24

Potential Role of Lixisenatide Among Glucagon-like Peptide-1 Receptor Agonist Medications
The first incretin-based therapy, exenatide, was launched in 2005. The novel mechanisms of action of GLP-1 agonists and their multiple associated benefits make them desirable options for the treatment of type 2 diabetes. The second incretin-based therapy to be approved, liraglutide, overcame some of the disadvantages of exenatide, including the need for multiple daily injections timed with meals and a relatively high incidence of nausea. Once-weekly exenatide (Bydureon®; Amylin Pharmaceuticals, Inc., Lilly USA, LLC, and Alkermes, Inc.) has been approved for use in Europe and is currently under review by the US Food and Drug Administration. Once-weekly administration will appeal to many patients, although the delivery system may not be as simple or as comfortable as those of the shorter-acting medications in this class. Medical providers will be able to offer patients the choice between the convenience of the once-weekly injection and the simplicity of the once-daily devices.

Review of the available data suggests that lixisenatide will be effective as a once-daily GLP-1 receptor agonist. Although it has a short half-life, similar to that of exenatide, its biological effects appear prolonged, perhaps due its higher affinity to the GLP-1 receptor. Once-daily administration of lixisenatide and twice-daily administration of exenatide achieved similar lowering of HbA1C levels in the GetGoal-X study.29

Lixisenatide has not been compared with liraglutide, the other once-daily GLP-1 agonist. Because liraglutide has a substantially longer half-life, it may reduce fasting plasma glucose more effectively than lixisenatide; however, potential slowing of gastric emptying with lixisenatide may result in greater improvements in post-prandial glucose levels. Additional clinical trials are required to confirm this. Data from further clinical trials and post-approval clinical experience will help clinicians decide how well lixisenatide compares with the other GLP-1 agonists.

Article Information:
Disclosure

The authors have no conflicts of interest to declare.

Correspondence

Mansur E Shomali, MD, CM, Division of Endocrinology, Diabetes and Metabolism, Union Memorial Hospital, 201 E. University Parkway, Baltimore, MD 21218. E: mansur.shomali@medstar.net

Received

2011-08-08T00:00:00

References

  1. Centers for Disease Control and Prevention, National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011; Atlanta, GA, Department of Health and Human Services.
  2. Shaw J, Sicree R, Zimmet P, Global estimates of the prevalence of diabetes for 2010 and 2030, Diabetes Res Clin Pract, 2010;87:4–14.
  3. Nathan DM, Buse JB, Davidson MB, et al., Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes, Diabetes Care, 2009;32:193–203.
  4. Rodbard HW, Blonde L, Braithwaite SS, et al., American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus, Endocr Pract, 2007;13(Suppl. 1):1–68.
  5. Garber AJ, Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability, Diabetes Care, 2011;34(Suppl. 2):S279–84.
  6. Drucker DJ, Nauck MA, The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes, Lancet, 2006;368:1696–1705.
  7. Pratley RE, Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes, Medscape J Med, 2008;10:171.
  8. Zealand Pharma A/S, Lixisenatide (Lyxumia®).
  9. Werner U, Haschke G, Herling AW, Kramer W, Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes, Regul Pept, 2010;164:58–64.
  10. Christensen M, Knop FK, Vilsboll T, Holst JJ, Lixisenatide for type 2 diabetes mellitus, Expert Opin Investig Drugs, 2011;20:549–57.
  11. Christensen M, Knop FK, Holst JJ, Vilsboll T, Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus, IDrugs, 2009;12:503–13.
  12. Thorkildsen C, Neve S, Larsen BD, et al., Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice, J Pharmacol Exp Ther, 2003;307:490–6.
  13. Werner U, Preclinical pharmacology of the new GLP-1 receptor agonist AVE0010, Ann Endocrinol (Paris), 2008;69:164–5.
  14. Becker R, Ruus P, Liu Y, Kapitza C, Restoration of insulin release with lixisenatide in patients with type 2 diabetes [abstract], Diabetologia, 2010;53(Suppl. 1):S339.
  15. Liu Y-H, Ruus P, Effect of the GLP-1 agonist AVE0010 on absorption of concomitant oral drugs, Diabetes, 2009; 58(Suppl. 1).
  16. Tews D, Werner U, Eckel J, Enhanced protection against cytokine- and fatty acid-induced apoptosis in pancreatic beta cells by combined treatment with glucagon-like peptide-1 receptor agonists and insulin analogues, Horm Metab Res, 2008;40:172–80.
  17. Haschke G, Haag-Diegarten S, Werner U, et al., The GLP-1 receptor agonist AVE0010 preserves beta cell function and insulin secretion after a 6 week treatment in male obese Zucker diabetic fatty rats – an isolated perfused pancreas study, Diabetologia, 2006;49(Suppl. 1):S400.
  18. Werner U, Vandewalle B, Kerr Conte J, et al., The GLP-1 receptor agonist AVE0010 improves GSIS, prevents lipotoxicityinduced insulin depletion and preserves β-cell function in human pancreatic islets, Diabetes, 2008;57(Suppl. 1).
  19. Werner U, Gerlach M, Hofmann M, Herling A, Treatment of obese Zucker diabetic fatty rats with novel GLP-1 receptor agonist AVE0010 improves oral glucose tolerance and glycaemic control without risk of hypoglycaemia, Diabetologia, 2006;49(Suppl. 1):398.
  20. Werner U, Gerlach M, Hofmann M, Herling AW, The GLP-1 receptor agonist AVE0010 abolishes OGTT-induced blood glucose excursion in healthy, normoglycemic dog without risk of hypoglycemia, Diabetes, 2007;56(Suppl. 1).
  21. Moore M, Werner U, Smith M, Rodewald T, Effect of the glucagon-like peptide-1 receptor agonist AVE0010 on postprandial hepatic glucose metabolism in the conscious dog, Diabetologia, 2007;50(Suppl. 1):S242.
  22. Werner U, Kuhlmann-Gottke J, Schafer H, Herling A, Effect of once-daily GLP1R agonist lixisenatide on gastric emptying and prandial carbohydrate utilization in animal models: a comparison with liraglutide, Diabetes, 2011;60(Suppl. 1).
  23. Huber J, Janecek E, Meister S, et al., Cardiogenic effect of GLP- 1 receptor agonist lixisenatide on ischemia-reperfusion-induced injury in the isolated rat heart, Diabetes, 2011;60(Suppl. 1).
  24. Ratner RE, Rosenstock J, Boka G, Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial, Diabet Med, 2010;27:1024–32.
  25. Distiller L, Ruus PE, Pharmacokinetics and pharmacodynamics of GLP-1 agonist AVE0010 in type 2 diabetes patients, Diabetes, 2008;57(Suppl. 1).
  26. Sanofi press release, Sanofi Getgoal programme on Lyxumia (lixisenatide), as an add-on to basal insulin, shows significant positive phase III results, June 3, 2011.
  27. Gerich J, Fonseca V, Alvarado-Ruiz R, et al., Monotherapy with GLP-1 receptor agonist, lixisenatide, significantly improves glycaemic control in type 2 diabetic patients, Diabetologia, 2010;53(Suppl. 1):S330.
  28. Seino Y, Min K, Niemoeller E, Takami A, Lixisenatide significantly improves glycemic control in Asian patients with T2DM insufficiently controlled on basal insulin +/- SU, Diabetes, 2011;60(Suppl. 1).
  29. Rosenstock J, Raccah D, Koranyi L, et al., Efficacy and safety of lixisenatide once-daily vs exenatide twice-daily in type 2 DM inadequately controlled on metformin, Diabetes, 2011; 60(Suppl. 1).
  30. Ratner R, et al., Efficacy and safety of lixisenatide once-daily versus placebo in patients with type 2 diabetes mellitus insufficiently controlled on sulfonylurea ± metformin (GetGoal-S), Presented at: 47th annual meeting of the European Association for the Study of Diabetes, Lisbon, Portugal, September 14, 2011.
  31. Drucker D, Minireview: the glucagon-like peptides, Endocrinology, 2001;142:521–7.
  32. Nauck MA, Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications, Am J Med, 2011;124:S3–18.
  33. Byetta package insert, San Diego, CA: Amylin Pharmaceuticals, Inc; 2010.
  34. Knudsen LB, Nielsen PF, Huusfeldt PO et al., Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration, J Med Chem, 2000;43:1664–9.
  35. Victoza package insert, Copenhagen, Denmark: Novo Nordisk A/S; 2011.
  36. Kim D, MacConell L, Zhuang D, et al., Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes, Diabetes Care, 2007;30:1487–93.
  37. Liu Y-H, Ruus P, Pharmacokinetics and safety of the GLP-1 agonist AAVE0010 in patients with renal impairment, Diabetes 2009;58(Suppl. 1).
  38. ClinicalTrials.gov, Identifier NCT00688701, GLP-1 agonist AVE0010 in patients with type 2 diabetes for glycemic control and safety evaluation in monotherapy (GETGOAL-MONO). Available at: http://clinicaltrials.gov/ct2/show/NCT00688701?term=lixisenati de&rank=8 (accessed December 19, 2011).
  39. ClinicalTrials.gov, Identifier NCT00866658, GLP-1 agonist AVE0010 in patients with type 2 diabetes for glycemic control and safety evaluation, on top of basal insulin +/- sulfonylurea (GETGOAL-L-ASIA). Available at: http://clinicaltrials.gov/ct2/show/NCT00866658?term=lixisenati de&rank=15 (accessed December 19, 2011).
  40. ClinicalTrials.gov, Identifier NCT00707031, GLP-1 agonist AVE0010 versus exenatide in patients with type 2 diabetes for glycemic control and safety evaluation, on top of metformin (GETGOAL-X). Available at: http://clinicaltrials.gov/ct2/show/NCT00707031?term=lixisenati de&rank=12 (accessed December 19, 2011).
  41. ClinicalTrials.gov, Identifier NCT00713830, GLP-1 agonist AVE0010 in patients with type 2 diabetes for glycemic control and safety evaluation, on top of sulfonylurea (GETGOAL-S). Available at: http://clinicaltrials.gov/ct2/show/NCT00713830? term=lixisenatide&rank=11 (accessed December 19, 2011).
  42. ClinicalTrials.gov, Identifier NCT00715624, GLP-1 agonist AVE0010 in patients with type 2 diabetes for glycemic control and safety evaluation, on top of basal insulin (GETGOAL-L). Available at: http://clinicaltrials.gov/ct2/show/NCT00715624?term=lixisenati de&rank=10 (accessed December 19, 2011).
  43. ClinicalTrials.gov, Identifier NCT00712673, GLP-1 agonist AVE0010 (morning or evening) in patients with type 2 diabetes for glycemic control and safety evaluation, on top of metformin (GETGOAL-M). Available at:http://clinicaltrials.gov/ct2/show/NCT00712673?term=lixisenati de&rank=17 (accessed December 19, 2011).
  44. ClinicalTrials.gov, Identifier NCT01169779, Efficacy and safety of lixisenatide in patients with type 2 diabetes mellitus insufficiently controlled by metformin (GETGOAL-M-As). Available at: http://clinicaltrials.gov/ct2/show/NCT01169779?term=lixisenati de&rank=2 (accessed December 19, 2011).
  45. ClinicalTrials.gov, Identifier NCT00763451, GLP-1 agonist AVE0010 in patients with type 2 diabetes for glycemic control and safety evaluation, on top of metformin (GETGOAL-F1). Available at:http://clinicaltrials.gov/ct2/show/NCT00763451?term=lixisenati de&rank=13 (accessed December 19, 2011).
  46. ClinicalTrials.gov, Identifier NCT00763815, GLP-1 agonist AVE0010 in patients with type 2 diabetes for glycemic control and safety evaluation, on top of pioglitazone (GETGOAL-P). Available from: http://clinicaltrials.gov/ct2/show/NCT00763815?term=lixisenati de&rank=9 (accessed December 19, 2011).
  47. ClinicalTrials.gov, Identifier NCT00905255, GLP-1 agonist AVE0010 in patients with type 2 diabetes for glycemic control and safety evaluation in monotherapy (GETGOAL-MONO Japan LTS). Available at: http://clinicaltrials.gov/ct2/show/NCT00905255?term=lixisenati de&rank=14 (accessed December 19, 2011).
  48. ClinicalTrials.gov, Identifier NCT00976937, 24-week study comparing lixisenatide (AVE0010) to sitagliptin as add-on to metformin in obese type 2 diabetic patients younger than 50. Available at: http://clinicaltrials.gov/ct2/show/NCT00976937?term=lixisenati de&rank=6 (accessed December 19, 2011).
  49. ClinicalTrials.gov, Identifier NCT00975286, 24-week treatment with lixisenatide in type 2 diabetes insufficiently controlled with metformin and insulin glargine (GetGoal Duo1). Available at: http://clinicaltrials.gov/ct2/show/NCT00975286?term=lixisenati de&rank=4 (accessed December 19, 2011).
  50. ClinicalTrials.gov, Identifier NCT01147250, Evaluation of cardiovascular outcomes in patients with type 2 diabetes after acute coronary syndrome during treatment with AVE0010 (lixisenatide) (ELIXA). Available at: http://clinicaltrials.gov/ct2/show/NCT01147250?term=lixisenati de&rank=3 (accessed December 19, 2011).
  51. Aronson R, et al., Efficacy and safety of lixisenatide QD morning and evening injections vs placebo in T2DM inadequately controlled on metformin (GetGoal-M), Presented at: 21st World Diabetes Congress, Dubai, UAE, December 8, 2011.
  52. Bolli GB, et al., Efficacy and safety of lixisenatide once-daily versus placebo in patients with type 2 diabetes mellitus insufficiently controlled on metformin (GetGoal-F1), Presented at: 47th annual meeting of the European Association for the Study of Diabetes, Lisbon, Portugal, September 14, 2011.
  53. Sanofi press release, Sanofi Reports Positive Results for Once-daily Lyxumia® (lixisenatide) in Combination with Lantus® (insulin glargine) in Type 2 Diabetes, December 6, 2011.

Further Resources

Share this Article
Related Content In Diabetes
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72